Fernandez-OrtizABadimonJJFalkEFusterVMeyerBMailhacA, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol1994; 23: 1562–1569.
2.
RosensonRSLoweGD.Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis1998; 140: 271–280. A comprehensive discussion on the influence of lipids and lipoproteins on thrombotic, fibrinolytic, and rheologic factors.
3.
BannerDWD'ArcyACheneCWinklerFKGuhaAKonigsbergWH, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature1996; 380: 41–46.
4.
MorenoPRBernardiVHLopez-CuellarJMurciaAMPalaciosIFGoldHK, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation1996; 94: 3090–3097.
5.
BadimonJJLettinoMToschiVFusterVBerrozpeMChesebroJH, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation1999; 99: 1780–1787. A study elucidating the role of tissue factor as a thrombotic agent in plaque disruption.
6.
AikawaMVoglicSJSugiyamaSRabkinETaubmanMBFallonJT, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation1999; 100: 1215–1222. A study done in rabbits testing the hypothesis that lipid lowering reduces tissue factor expression and activity. Diminished activity was associated with a decreased expression of CD40L and CD40, a trigger of tissue factor expression by macrophages in human atheroma.
7.
ColliSEliginiSLalliMCameraMPaolettiRTremoliE.Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol1997; 17: 265–272.
8.
RauchUOsendeJIChesebroJHFusterVVorchheimerDAHarrisK, et al. Statins and cardiovascular diseases: The multiple effects of lipid lowering therapy by statins. Atherosclerosis2000; 153: 181–189. A study done in hypercholesterolaemic patients testing two hypotheses. The first was that a reduction of plasma lipid levels with statins reduces blood thrombogenicity and endothelial dysfunction. Second, was that the decreased thrombogenicity of blood and endothelium was associated with a decreased number of circulating soluble adhesion molecules.
9.
DangasGSmithDAUngerAHShaoJHMerajPFierC, et al. Pravastatin: An anti-thrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost2000; 83: 688–692. A prospective six-month study of statin therapy illustrating that the diminished thrombogenicity provided by statin therapy was not proportional to the magnitude of LDL-C reduction. The study suggests that statins do more than diminish LDL-C and must have other affects causing the marked reduction in thrombogenicity.
10.
CarvalhoACColmanRWLeesRS.Platelet function in hyperlipoproteinemia. N Engl J Med1974; 290: 434–438.
11.
van WilligenGGorterGAkkermanJW.LDLs increase the exposure of fibrinogen binding sites on platelets and secretion of dense granules. Arterioscler Thromb1994; 14: 41–46.
12.
Le QuanSang KHLevensonJMegnienJLSimonADevynckMA.Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolaemia. Effects of pravastatin. Arterioscler Thromb Vasc Biol1995; 15: 759–764.
13.
NotarbartoloADaviGAvernaMBarbagalloCMGanciAGiammarresiC, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolaemia. Arterioscler Thromb Vasc Biol1995; 15: 247–251.
14.
AokiIAokiNKawanoKShimoyamaKMakiAHomoriM, et al. Platelet-dependent thrombin generation in patients with hyperlipidaemia. J Am Coll Cardiol1997; 30: 91–96.
15.
LacosteLLamJYTComparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolaemic coronary patients. J Am Coll Cardiol1996; 27: 413A.
16.
SweetnamPMThomasHFYarnellJWBeswickADBakerIAElwoodPC.Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. Eur Heart J1996; 17: 1814–1820.
17.
ThompsonSGKienastJPykeSDHaverkateFvan de LooJC.Haemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med1995; 332: 635–641.
18.
BeigelYFuchsJSnirMGreenPLurieYDjaldettiM.Lovastatin therapy in hypercholesterolaemia: Effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol1991; 31: 512–517.
19.
DavidsonMMcKenneyJSteinESchrottHBakker-ArkemaRFayyadR, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolaemia. Atorvastatin Study Group I. Am J Cardiol1997; 79: 1475–1481.
20.
HaffnerSOrchardTSteinESchmidtDLaBelleP.Effect of simvastatin on Lp(a) concentrations. Clin Cardiol1995; 18: 261–267.
21.
HarpelPCGordonBRParkerTS.Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA1989; 86: 3847–3851.
22.
KoenigWHehrRDitschuneitHHKuhnKErnstERosenthalJ, et al. Lovastatin alters blood rheology in primary hyperlipoproteinemia: Dependence on lipoprotein (a)? J Clin Pharmacol1992; 32: 539–545.
23.
MayerJEllerTBrauerPSollederEMSchaferRMKellerF, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol1992; 64: 196–201.
24.
MitropoulosKAArmitageJMCollinsRMeadeTWReevesBEWallendszusKR, et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. Eur Heart J1997; 18: 235–241.
25.
DiCorletoPGimbroneMA.Vascular endothelium. In: FusterVRossRTopolES (editors): Atherosclerosis and coronary artery disease. Vol. 1Philadelphia: Lippincott-Raven; 1996 p. 387.
26.
LudmerPLSelwynAPShookTLWayneRRMudgeGHAlexanderRW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med1986; 315: 1046–1051.
27.
LiaoJKShinWSLeeWYClarkSL.Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem1995; 270: 319–324.
28.
LaufsULa FataVPlutzkyJLiaoJK.Up-regulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation1998; 97: 1129–1135.
29.
WilliamsJKSukhovaGKHerringtonDMLibbyP.Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol1998; 31: 684–691.
30.
FusterV.Plaque Stabilization. In: FusterV (editors): The vulnerable atherosclerotic plaque: understanding, identification, and modification. Armonk, NY: Futura Publishing Company Inc.; 1999 pp. 393–412.
31.
EgashiraKHirookaYKaiHSugimachiMSuzukiSInouT, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolaemia. Circulation1994; 89: 2519–2524.
32.
O'DriscollGGreenDTaylorRR.Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation1997; 95: 1126–1131.
33.
GouldKLMartucciJPGoldbergDIHessMJEdensRPLatifiR, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential non-invasive marker of healing coronary endothelium. Circulation1994; 89: 1530–1538.
34.
EichstadtHWEskotterHHoffmanIAmthauerHWWeidingerG.Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol1995; 76: 122A–125A.
35.
AndrewsTCRabyKBarryJNaimiCLAllredEGanzP, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease [see comments]. Circulation1997; 95: 324–328.
36.
van BovenAJJukemaJWZwindermanAHCrijnsHJLieKIBruschkeAV.Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation1996; 94: 1503–1505.
37.
MorenoPRFalkEPalaciosIFNewellJBFusterVFallonJT.Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation1994; 90: 775–778.
38.
LibbyP.Molecular bases of the acute coronary syndromes. Circulation1995; 91: 2844–2850. A comprehensive review detailing the molecular mechanisms of acute coronary syndromes.
39.
FusterVFayadZABadimonJJ.Acute coronary syndromes: Biology. Lancet1999; 353: 5–9. An extensive review of the biological phenomena causing acute coronary syndromes. The article explains the molecular mechanisms and correlates them with clinical syndromes. Future therapies with apoptotic and tissue factor inhibitors and the role of new imaging technologies are explored.
40.
ShahPKFalkEBadimonJJFernandez-OrtizAMailhacAVillareal-LevyG, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation1995; 92: 1565–1569.
41.
AikawaMRabkinEOkadaYVoglicSJClintonSKBrinckerhoffCE, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization. Circulation1998; 97: 2433–2444.
42.
SteinbergD.Oxidative modification of LDL and atherogenesis. Circulation1997; 95: 1062–1072.
43.
AviramMDanknerGCoganUHochgrafEBrookJG.Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies. Metabolism1992; 41: 229–235.
44.
KimuraMKuroseIRussellJGrangerDN.Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolaemic rats. Arterioscler Thromb Vasc Biol1997; 17: 1521–1526.
45.
WeberCErlWWeberKSWeberPC.HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolaemia. J Am Coll Cardiol1997; 30: 1212–1217.
46.
Negre-AminouPvan VlietAKvan ErckMvan ThielGCvan LeeuwenRECohenLH.Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta1997; 1345: 259–268.
47.
MartinAJGotliebAIHenkelmanRM.High-resolution MR imaging of human arteries. J Magn Reson Imaging1995; 5: 93–100.
48.
ToussaintJFLaMuragliaGMSouthernJFFusterVKantorHL.Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation1996; 94: 932–938.
49.
ShinnarMFallonJTWehrliSLevinMDalmacyDFayadZA, et al. The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. Arterioscler Thromb Vasc Biol1999; 19: 2756–2761.
50.
FayadZANaharTFallonJTGoldmanMAguinaldoJGBadimonJJ, et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: A comparison with transesophageal echocardiography. Circulation2000; 101: 2503–2509. An in vivo study using MR imaging evaluating atherosclerotic plaque size, extent and composition in human thoracic aorta. The study demonstrates the power and utility of MR imaging of atherosclerotic disease.
51.
FayadZFusterV.Characterization of atherosclerotic plaques by magnetic resonance imaging. Annals of the New York Academy of Science2000; 902: 173–186.
52.
FayadZAFusterVFallonJTJayasunderaTWorthleySGHelftG, et al. Non-invasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation2000; 102: 506–510. An in vivo study using MR imaging demonstrated improved plaque characterization in human coronary arteries. MR imaging allows evaluation of plaque content and may become a useful diagnostic tool for detection of vulnerable lesions.
53.
van der WallEEVliegenHWde RoosABruschkeAV.Magnetic resonance imaging in coronary artery disease. Circulation1995; 92: 2723–2739.
54.
PostMJBorstCKuntzRE.The relative importance of arterial remodeling compared with intimal hyperplasia in lumen re-narrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolaemic Yucatan micropig. Circulation1994; 89: 2816–2821.
55.
SmallDM.George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis1988; 8: 103–129.
56.
CallisterTQRaggiPCooilBLippolisNJRussoDJ.Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med1998; 339: 1972–1978.
57.
CortiRFusterVFayadZAWorthleySGHelftGSmithD, et al. Lipid-lowering by simvastatin induces regression of human atherosclerotic lesions: 2 years follow-up by high resolution noninvasive MRI. Circulation2002; 106: 2884–2887.
58.
RosensonRSTangneyCC.Anti-atherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA1998; 279: 1643–1650.
59.
VaughanCJMurphyMBBuckleyBM.Statins do more than just lower cholesterol. Lancet1996; 348: 1079–1082.
